Find a Clinical Trial

Showing 161 - 170 of 231 Trials

  • PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTSWITH SYMPTOMATIC MULTIPLE MYELOMA

    Principal Investigator:

    Rajshekar Chakraborty, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05828511

    Population:

    Adult

    Phase:

    I/II
    This study is looking at people who have recently been newly diagnosed with a type of cancer called multiple myeloma (NDMM). The purpose of this study is to learn about the safety, tolerability (how your body reacts to the study drug), and effectiveness (tumor shrinkage) of linvoseltamab (called “study drug”) in participants with NDMM as a first step in determining if the study drug has a role to play in the treatment of NDMM. This study consists of 2 phases. Your study doctor will tell you which phase of the study you will be participating in. Are you Eligible? (Inclusion...

  • Phase 1b/2 Study of ATR InhibiTor RP-3500 and PARP Inhibitor Combinations in Patients with Molecularly Selected Cancers (ATTACC)

    Principal Investigator:

    Benjamin Herzberg, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT04972110

    Population:

    Adult

    Phase:

    I/II
    The study is being done to learn how safe and effective the study drug, RP- 3500, is when given with either niraparib or olaparib to treat advanced cancer. Niraparib and olaparib belong to a group of drugs called PARP inhibitors. These drugs are designed to block an enzyme called PARP which may stop cancer cells from growing. RP 3500 belongs to a class of drugs called ATR inhibitors that are design to stop cancer cells from growing. Are you Eligible? (Inclusion Criteria) Aged 18 years or older. Diagnosed with locally advanced or metastatic cancer. Have not received prior therapy with another...

  • A Phase 1 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+Stem Cells Transduced Ex Vivo with the LentiGlobin BB305 Lentiviral Vector inSubjects with Severe Sickle Cell Disease

    Principal Investigator:

    Markus Y Mapara, MD

    Contact Number:

    212-342-5162

    Phase:

    I
    The purpose of this study is to evaluate the safety and ability of the autologous stem cell transplant with gene modified stem cells to treat sickle cell disease. The goal is to determine if a sufficient amount of normal hemoglobin (without sickling) can be produced after the gene modified stem cells are returned to the body. This study may provide information on the usefulness of LentiGlobin® BB305 as a future treatment for sickle cell disease. Genes, which we inherit from our parents, are pieces of information which provide the blueprints for all the proteins that keep our cells and...

  • A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, as a Single Agent and as Combination Therapy in Patients with Advanced Solid Malignancies and Lymphoma with an Expansion in Select Malignancies

    Principal Investigator:

    June Y. Hou, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT02922764

    Population:

    Adult

    Phase:

    I
    The main purpose of this study is learn about the the safety and side effects of the study drug, RGX-104. RGX-104 is an experimental drug. This means that RGX-104 is not approved by the Food and Drug Administration (FDA). This is the first time RGX-104 will be given to humans. Are you Eligible? (Inclusion Criteria) Do you have a confirmed solid tumor? Have you had treatment for your disease before? Or is there not a standard treatment available for your disease? Does your cancer continue to grow? Can your cancer not be removed by surgery? Are you 18 years of age or older?

  • A Pilot Study of Neoadjuvant Combination Spartalizumab and Canakinumab Prior to Radical Nephrectomy in Patients with Localized Clear Cell Renal Cell Carcinoma (SPARC-1 Trial)

    Principal Investigator:

    Karie Danielle Keera Runcie, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT04028245

    Population:

    Adult

    Phase:

    I
    The purpose of this study is to study two experimental drugs called canakinumab and spartalizumab produced by Novartis to see if: • It is safe and feasible to give canakinumab and spartalizumab prior to radical nephrectomy? • Canakinumab and spartalizumab can kill cancer cells and bring immune cells into the kidney cancer when hen given to human subjects prior to radical nephrectomy? You are being asked to participate in this study because you have localized kidney cancer and you are planned to have a radical nephrectomy. People who usually have this do not receive any additional...

  • A Phase 1 Study to Evaluate the Safety and Tolerability of AB680 Combination Therapy in Participants with Gastrointestinal Malignancies

    Principal Investigator:

    Gulam A. Manji, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT04104672

    Population:

    Adult

    Phase:

    I
    This study is being done to see if potential new drugs, AB680 and AB122, can be safely given in combination with chemotherapy to study patients with pancreatic cancer. The standard chemotherapy treatments that will be given in combination with AB680 and AB122 are nab-paclitaxel and gemcitabine. AB680 and AB122 are are not approved by the United States Food and Drug Administration (U.S. FDA). Are you Eligible? (Inclusion Criteria) Are you at least 18 years old? Do you have histologically or cytologically confirmed metastatic pancreatic adenocarcinoma? Are you naïve to any prior treatment...

  • A Phase 1/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 inPatients with Mature B-Cell Malignancies

    Principal Investigator:

    Nicole Lamanna, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT04277637

    Population:

    Adult

    Phase:

    I
    The purpose of this study is to look at the safety and tolerability of an investigational anticancer drug currently known as BGB-11417. This study aims to determine the range of BGB-11417 doses that can safely be used, the safest dosing schedule to minimize side effects when first taking BGB-11417, what side effects may be experienced when taking this drug, how your body processes this drug, and if this drug is effective against your cancer. Are you Eligible? (Inclusion Criteria) Provision of signed and dated written informed consent prior to any study specific procedures, sampling, or...

  • A phase 1/1b dose escalation study of abemaciclib and olaparib for recurrent platinum-resistant ovarian cancer

    Principal Investigator:

    Jason D. Wright, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT04633239

    Population:

    Adult

    Phase:

    I
    This study is being done to answer the following question: Can abemaciclib and olaparib be taken safely together in ovarian cancer that has come back? We are asking you to take part in this research study because you have ovarian cancer that has come back. We are trying to determine whether abemaciclib and olaparib can be taken safely and tolerably together in ovarian cancer that has come back. Are you Eligible? (Inclusion Criteria) Must have ovarian cancer that has come back within 6 months of last dose of treatment. Must have received 1-3 prior treatment regimens. Must have lesions seen on...

  • An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) In Adult Participants with Advanced Solid Tumors

    Principal Investigator:

    Benjamin Herzberg, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT04794699

    Population:

    Adult

    Phase:

    I
    IDE397 is an investigational drug, which has not been approved by health authorities for the treatment of people with your medical condition. It is currently not “on the market” (available for you to receive a prescription for and/or to buy) in any country. In this study, different dose levels of IDE397 will be tested. About 40 patients are expected to participate at approximately 6-8 study centers within the US. At a minimum, 2 patients will be enrolled in each dose level. There will be about 10 dose levels tested (starting at 5 mg). Every time a dose level is found to be safe, a...

  • A Phase 1 Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer

    Principal Investigator:

    Mark N. Stein, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT04898634

    Population:

    Adult

    Phase:

    I
    You are being invited to take part in a research study that includes studying JNJ-78278343 in subjects with prostate cancer. This is an investigational drug which means that this is a new approach for the treatment of people who have prostate cancer. The main purpose of this study is to find a safe dose of JNJ- 78278343 that can be used in the treatment of prostate cancer. To do this, we must find out if JNJ-78278343 can cause side-effects. Also, we need to find out how long JNJ-78278343 stays in and acts on your body and how your body responds to it. Prostate cancer is known to have high...

Pages